- call +1-201-465-4211
- email sales@mrinsights.biz
Epilepsy is associated with disrupted activities in the brain called seizures, which affects the central nervous system. Depending on the area of the brain obstructed by seizures, these are categorized into generalized seizures and partial seizures. Generalized seizures affect the whole brain, while partial seizures affect just one part of the brain. Depending on their severity, seizures are termed as mild seizures and stronger seizures. Mild seizures are difficult to diagnose, as these last for only a few seconds. Stronger seizures may last for a few seconds to a few or several minutes, resulting in spasms and uncontrollable muscle twitches. This may cause the patient to lose consciousness, lead to temporary loss of cognition, or memory loss during the seizure. Pediatric epilepsy can be caused due to a trauma injury, complications during birth, or genetic disorder. Epilepsy that occurs due to brain infections such as meningitis is known as symptomatic epilepsy, while genetics related condition is called idiopathic epilepsy.
Scope of the Report:
This report focuses on the Anti-epileptic Drugs for Pediatrics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Anti-epileptic Drugs for Pediatrics is expected to grow at a CAGR of roughly 7.3% over the next five years, will reach 1270 million US$ in 2023, from 830 million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Mylan N.V
Cephalon, Inc
GlaxoSmithKline plc
Janssen Pharmaceuticals
Novartis AG
Pfizer, Inc
Sanofi S.A
UCB Pharma Limited
Sunovion Pharmaceuticals Limited
Valeant Pharmaceuticals International, Inc
Zogenix
GW Pharmaceuticals
Insys
Zynerba
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
1st generation
2nd generation
3rd generation
Market Segment by Applications, can be divided into
Hospitals
Retail pharmacies
Online pharmacies
There are 15 Chapters to deeply display the global Anti-epileptic Drugs for Pediatrics market.
Chapter 1, to describe Anti-epileptic Drugs for Pediatrics Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Anti-epileptic Drugs for Pediatrics, with sales, revenue, and price of Anti-epileptic Drugs for Pediatrics, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-epileptic Drugs for Pediatrics, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Anti-epileptic Drugs for Pediatrics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Anti-epileptic Drugs for Pediatrics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Anti-epileptic Drugs for Pediatrics Introduction
1.2 Market Analysis by Type
1.2.1 1st generation
1.2.2 2nd generation
1.2.3 3rd generation
1.3 Market Analysis by Applications
1.3.1 Hospitals
1.3.2 Retail pharmacies
1.3.3 Online pharmacies
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Mylan N.V
2.1.1 Business Overview
2.1.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Mylan N.V Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Cephalon, Inc
2.2.1 Business Overview
2.2.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Cephalon, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 GlaxoSmithKline plc
2.3.1 Business Overview
2.3.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 GlaxoSmithKline plc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Janssen Pharmaceuticals
2.4.1 Business Overview
2.4.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Janssen Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Novartis AG
2.5.1 Business Overview
2.5.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Novartis AG Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Pfizer, Inc
2.6.1 Business Overview
2.6.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Pfizer, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Sanofi S.A
2.7.1 Business Overview
2.7.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Sanofi S.A Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 UCB Pharma Limited
2.8.1 Business Overview
2.8.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 UCB Pharma Limited Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Sunovion Pharmaceuticals Limited
2.9.1 Business Overview
2.9.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Sunovion Pharmaceuticals Limited Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.10 Valeant Pharmaceuticals International, Inc
2.10.1 Business Overview
2.10.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Valeant Pharmaceuticals International, Inc Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.11 Zogenix
2.11.1 Business Overview
2.11.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Zogenix Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.12 GW Pharmaceuticals
2.12.1 Business Overview
2.12.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 GW Pharmaceuticals Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.13 Insys
2.13.1 Business Overview
2.13.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Insys Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.14 Zynerba
2.14.1 Business Overview
2.14.2 Anti-epileptic Drugs for Pediatrics Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Zynerba Anti-epileptic Drugs for Pediatrics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Anti-epileptic Drugs for Pediatrics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Anti-epileptic Drugs for Pediatrics Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Anti-epileptic Drugs for Pediatrics Manufacturer Market Share in 2017
3.3.2 Top 6 Anti-epileptic Drugs for Pediatrics Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Anti-epileptic Drugs for Pediatrics Market Analysis by Regions
4.1 Global Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Regions
4.1.1 Global Anti-epileptic Drugs for Pediatrics Sales and Market Share by Regions (2013-2018)
4.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Regions (2013-2018)
4.2 North America Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
4.3 Europe Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
4.5 South America Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
5 North America Anti-epileptic Drugs for Pediatrics by Countries
5.1 North America Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Countries
5.1.1 North America Anti-epileptic Drugs for Pediatrics Sales and Market Share by Countries (2013-2018)
5.1.2 North America Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Countries (2013-2018)
5.2 United States Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
5.3 Canada Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
5.4 Mexico Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
6 Europe Anti-epileptic Drugs for Pediatrics by Countries
6.1 Europe Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Countries
6.1.1 Europe Anti-epileptic Drugs for Pediatrics Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Countries (2013-2018)
6.2 Germany Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
6.3 UK Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
6.4 France Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
6.5 Russia Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
6.6 Italy Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
7 Asia-Pacific Anti-epileptic Drugs for Pediatrics by Countries
7.1 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Anti-epileptic Drugs for Pediatrics Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Countries (2013-2018)
7.2 China Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
7.3 Japan Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
7.4 Korea Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
7.5 India Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
8 South America Anti-epileptic Drugs for Pediatrics by Countries
8.1 South America Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Countries
8.1.1 South America Anti-epileptic Drugs for Pediatrics Sales and Market Share by Countries (2013-2018)
8.1.2 South America Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
8.3 Argentina Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
8.4 Colombia Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
9 Middle East and Africa Anti-epileptic Drugs for Pediatrics by Countries
9.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Anti-epileptic Drugs for Pediatrics Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
9.3 UAE Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
9.4 Egypt Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
9.5 Nigeria Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
9.6 South Africa Anti-epileptic Drugs for Pediatrics Sales and Growth Rate (2013-2018)
10 Global Anti-epileptic Drugs for Pediatrics Market Segment by Type
10.1 Global Anti-epileptic Drugs for Pediatrics Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Anti-epileptic Drugs for Pediatrics Sales and Market Share by Type (2013-2018)
10.1.2 Global Anti-epileptic Drugs for Pediatrics Revenue and Market Share by Type (2013-2018)
10.2 1st generation Sales Growth and Price
10.2.1 Global 1st generation Sales Growth (2013-2018)
10.2.2 Global 1st generation Price (2013-2018)
10.3 2nd generation Sales Growth and Price
10.3.1 Global 2nd generation Sales Growth (2013-2018)
10.3.2 Global 2nd generation Price (2013-2018)
10.4 3rd generation Sales Growth and Price
10.4.1 Global 3rd generation Sales Growth (2013-2018)
10.4.2 Global 3rd generation Price (2013-2018)
11 Global Anti-epileptic Drugs for Pediatrics Market Segment by Application
11.1 Global Anti-epileptic Drugs for Pediatrics Sales Market Share by Application (2013-2018)
11.2 Hospitals Sales Growth (2013-2018)
11.3 Retail pharmacies Sales Growth (2013-2018)
11.4 Online pharmacies Sales Growth (2013-2018)
12 Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.1 Global Anti-epileptic Drugs for Pediatrics Sales, Revenue and Growth Rate (2018-2023)
12.2 Anti-epileptic Drugs for Pediatrics Market Forecast by Regions (2018-2023)
12.2.1 North America Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.2.2 Europe Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.2.3 Asia-Pacific Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.2.4 South America Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.2.5 Middle East and Africa Anti-epileptic Drugs for Pediatrics Market Forecast (2018-2023)
12.3 Anti-epileptic Drugs for Pediatrics Market Forecast by Type (2018-2023)
12.3.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Type (2018-2023)
12.3.2 Global Anti-epileptic Drugs for Pediatrics Market Share Forecast by Type (2018-2023)
12.4 Anti-epileptic Drugs for Pediatrics Market Forecast by Application (2018-2023)
12.4.1 Global Anti-epileptic Drugs for Pediatrics Sales Forecast by Application (2018-2023)
12.4.2 Global Anti-epileptic Drugs for Pediatrics Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Anti-epileptic Drugs for Pediatrics Picture
Table Product Specifications of Anti-epileptic Drugs for Pediatrics
Figure Global Sales Market Share of Anti-epileptic Dr
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
